Following the 2017 launches of two atopic dermatitis novel therapies, Pfizer’s topical PDE-4 inhibitor Eucrisa (crisaborole) and Sanofi/Regeneron’s IL-4/13 inhibitor Dupixent (dupilumab), the U.S. treatment and market access landscape for atopic dermatitis is evolving. Topical agents are the mainstay of treatment for atopic dermatitis, especially for patients with mild to moderate disease. Eucrisa provides a much needed alternative to topical corticosteroids and topical calcineurin inhibitors. Dupixent has given moderate to severe atopic dermatitis patients a promising targeted therapy option, with AstraZeneca/Leo Pharma’s tralokinumab, Galderma’s nemolizumab, Vanda’s tradipitant, and multiple JAK inhibitors potentially strengthening the field in the near future. Payers look to manage utilization of therapies to control costs in the wake of the more recent premium-priced entrants in this previously genericized market.
- What are current prescribing practices for atopic dermatitis, and how are they impacted by payer policy?
- How has the market entry of Eucrisa and Dupixent influenced physician prescribing and payer policy?
- How will dermatologists’ prescribing of established agents by line of therapy shift with the recent entry of Eucrisa and Dupixent?
- What are payer and physician perspectives on promising but costly emerging agents such as tralokinumab, nemolizumab, tradipitant, and JAK inhibitors?
Geography: United States
Primary Research: Survey of 100 U.S. dermatologists Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)
Key Drugs Covered: Dupixent, Eucrisa, Protopic, Elidel, CellCept, Neoral/Sandimmune, Temovate/Olux/Clobex, Aristocort/Kenalog, tralokinumab, nemolizumab, tradipitant, baricitinib, upadacitinib, abrocitinib
Content Highlights: Reimbursement and contracting Access and prescribing Special topics Opportunities and challenges for emerging therapies
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.
- Atopic Dermatitis/Atopic Eczema - Access & Reimbursement - Detailed, Expanded Analysis (US)
- Access & Reimbursement Atopic Dermatitis US May 2019
Author(s): Ritesh Gupta, Ph.D.; Chris Lewis
Ritesh is a manager in the Immune and Inflammatory Disorders team at DRG, part of Clarivate. He has years of experience in competitive intelligence, scientific analysis, and market opportunity assessment and has worked in various therapeutic areas to provide strategic recommendations to pharmaceutical companies. He holds a Ph.D. in cell biology from the Max Delbrück Center for Molecular Medicine in Berlin.
Chris Lewis is a primary research manager at DRG, part of Clarivate. She is responsible for the coordination, content review, and content generation of DRG’s U.S. Access & Reimbursement reports, including authoring select A&R reports on managed care trends. Before this position, Ms. Lewis was a senior analyst for DRG’s HealthLeaders-InterStudy subsidiary. She analyzed the managed care markets in California, New York, and Pennsylvania. She also launched and authored DRG’s Pharmacy Benefit Manager profile series. She received her bachelor’s degree from California State University in Sacramento.